2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Nasopharyngeal Carcinoma
11
Leukemia, Myeloid, Acute
4
Carcinoma, Non-Small-Cell Lung
4
Nasopharyngeal Neoplasms
3
Lung Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Rectal Neoplasms
2
Myelodysplastic Syndromes
2
Turcot syndrome
1
Tongue Neoplasms
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Rhabdoid Tumor
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Patient Outcome Assessment
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoma
1
Locally Advanced Malignant Neoplasm
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Hypopharyngeal Neoplasms
1
Interventions
Carboplatin
8
Trastuzumab
6
Docetaxel
5
pembrolizumab
4
Paclitaxel
4
Oxaliplatin
4
Fluorouracil
4
Cytarabine
4
Cyclophosphamide
4
Azacitidine
4
pertuzumab
3
Radiotherapy
3
Observation
3
Neoadjuvant Therapy
3
Epirubicin
3
Endoscopy
3
Cisplatin
3
Chemoradiotherapy
3
Capecitabine
3
130-nm albumin-bound paclitaxel
3
venetoclax
2
toripalimab
2
sargramostim
2
olaparib
2
durvalumab
2
cc-486
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Pemetrexed
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Induction Chemotherapy
×
Clear all
NCT07472868
2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3
Not yet recruiting
394 enrolled